Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2018 -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on February 20, 2018, the compensation committee of the Company's board of directors granted six new employees the option to purchase an aggregate of 20,670 shares of the Company's common stock and 10,360 restricted stock units. Each stock option has an exercise price per share equal to $10.75, which was the closing trading price on February 20, 2018. The stock options and restricted stock units were granted pursuant to the Company's 2014 Employment Commencement Incentive Plan, as amended, which was approved by the Company's board of directors in December 2014 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. The Food and Drug Administration has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. The Company's second product candidate is C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination. Achaogen's plazomicin program has been funded, and its C-Scape program is funded, in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA). Achaogen has other programs in early and late preclinical stages of development focused on other MDR gram-negative infections and additional disease areas. All product candidates, including plazomicin, are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.
Source: Achaogen, Inc. (NASDAQ:AKAO)
Investor Contact:
Ashley R. Robinson
LifeSci Partners, LLC
[email protected]
Media Contact:
Denise T. Powell
Red House Consulting, LLC
[email protected]
